Kura Oncology (NASDAQ:KURA) Upgraded to “Hold” at StockNews.com

StockNews.com upgraded shares of Kura Oncology (NASDAQ:KURAFree Report) from a sell rating to a hold rating in a report released on Wednesday morning.

A number of other research analysts also recently commented on the stock. Mizuho began coverage on shares of Kura Oncology in a research report on Friday, December 22nd. They issued a buy rating and a $26.00 target price on the stock. HC Wainwright reissued a buy rating and set a $32.00 price objective on shares of Kura Oncology in a research report on Wednesday, March 6th. JMP Securities raised their price objective on shares of Kura Oncology from $22.00 to $32.00 and gave the stock a market outperform rating in a research report on Wednesday, January 31st. Finally, Wedbush reissued an outperform rating and set a $37.00 price objective on shares of Kura Oncology in a research report on Wednesday, February 28th. Two analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of Moderate Buy and an average price target of $28.28.

Read Our Latest Research Report on KURA

Kura Oncology Trading Down 0.9 %

NASDAQ KURA opened at $20.34 on Wednesday. The company has a debt-to-equity ratio of 0.02, a current ratio of 12.26 and a quick ratio of 12.26. The firm’s fifty day moving average price is $20.94 and its 200 day moving average price is $14.35. The company has a market capitalization of $1.55 billion, a price-to-earnings ratio of -9.78 and a beta of 0.85. Kura Oncology has a 12 month low of $7.41 and a 12 month high of $24.17.

Kura Oncology (NASDAQ:KURAGet Free Report) last posted its earnings results on Tuesday, February 27th. The company reported ($0.55) EPS for the quarter, beating analysts’ consensus estimates of ($0.56) by $0.01. During the same quarter in the previous year, the company earned ($0.49) earnings per share. On average, sell-side analysts expect that Kura Oncology will post -2.35 earnings per share for the current fiscal year.

Insider Activity

In other news, CEO Troy Edward Wilson sold 91,052 shares of Kura Oncology stock in a transaction dated Wednesday, January 24th. The shares were sold at an average price of $20.23, for a total value of $1,841,981.96. Following the sale, the chief executive officer now owns 559 shares of the company’s stock, valued at $11,308.57. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other news, CEO Troy Edward Wilson sold 91,052 shares of Kura Oncology stock in a transaction dated Wednesday, January 24th. The shares were sold at an average price of $20.23, for a total value of $1,841,981.96. Following the sale, the chief executive officer now owns 559 shares of the company’s stock, valued at $11,308.57. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, COO Kathleen Ford sold 1,496 shares of Kura Oncology stock in a transaction dated Monday, January 29th. The shares were sold at an average price of $17.80, for a total transaction of $26,628.80. Following the completion of the sale, the chief operating officer now directly owns 21,602 shares in the company, valued at approximately $384,515.60. The disclosure for this sale can be found here. Insiders have sold a total of 96,919 shares of company stock valued at $1,946,415 over the last quarter. Corporate insiders own 5.60% of the company’s stock.

Institutional Trading of Kura Oncology

Hedge funds and other institutional investors have recently made changes to their positions in the stock. US Bancorp DE lifted its stake in shares of Kura Oncology by 45.0% in the fourth quarter. US Bancorp DE now owns 2,097 shares of the company’s stock valued at $30,000 after purchasing an additional 651 shares during the period. Tower Research Capital LLC TRC lifted its stake in shares of Kura Oncology by 46.8% in the second quarter. Tower Research Capital LLC TRC now owns 4,710 shares of the company’s stock valued at $50,000 after purchasing an additional 1,501 shares during the period. Signaturefd LLC grew its position in shares of Kura Oncology by 40.4% in the fourth quarter. Signaturefd LLC now owns 5,038 shares of the company’s stock valued at $72,000 after purchasing an additional 1,449 shares during the last quarter. Royal Bank of Canada increased its stake in shares of Kura Oncology by 81.5% during the 2nd quarter. Royal Bank of Canada now owns 6,801 shares of the company’s stock worth $72,000 after purchasing an additional 3,053 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. increased its stake in shares of Kura Oncology by 352.6% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 8,590 shares of the company’s stock worth $124,000 after purchasing an additional 6,692 shares in the last quarter.

Kura Oncology Company Profile

(Get Free Report)

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.

See Also

Analyst Recommendations for Kura Oncology (NASDAQ:KURA)

Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.